Artificial intelligence (AI) is transforming biotechnology, providing new ways to accelerate the research and development of innovative therapies. From target identification to preclinical testing, AI and machine learning are being applied across the biopharma value chain to enhance R&D productivity. In this post, we’ll explore how AI is overcoming key bottlenecks, enabling faster and more efficient biotech research and production cycles.
Target Identification and Validation
One of the biggest bottlenecks in biotech R&D is identifying promising targets to even begin investigating. There are estimated to be over 3,000 disease-associated proteins encoded in the human genome, but researchers struggle to pinpoint which ones represent viable drug targets. Analyzing huge datasets of genetic information, chemical structures, and clinical data to uncover potential targets is enormously time-consuming using traditional techniques.
AI is stepping in to rapidly predict protein targets, cutting target identification timelines by up to 70%. Deep learning algorithms can churn through massive biomedical datasets, uncovering subtle patterns missed by human analysis. BenevolentAI developed an AI system that combed through scientific papers and databases to predict approved and experimental drug interactions with a 75% accuracy rate. What used to take months to years of painstaking research can now be accomplished in weeks with AI target prediction.
Once promising targets are identified, they need to be biologically validated before pursuing further. Typically this involves extensive lab testing and clinical trials, requiring 3-5 years per target with low success rates. AI-based simulation models can simulate target behavior and probabilistically determine validation potential in silico. Insilico Medicine uses generative adversarial networks (GANs) to generate synthetic data mimicking real biological system responses, predicting validation outcomes with 86% accuracy. By weeding out unlikely targets earlier, AI simulation can save years of wasted research on invalid targets.
Hit Generation and Lead Optimization
The next R&D phase involves high-throughput screening of chemical libraries to find “hit” compounds that interact with the target. Libraries can contain millions of diverse compounds, so testing them against targets one-by-one is tedious and expensive. AI virtual screening tools can narrow down the search space, predicting the most promising candidates for physical screening.
Exscientia developed an AI platform that designed and evaluated over 3 million novel drug-like compounds in just 12 months for a target associated with immune disorders. The top 15 predicted compounds showed significant target affinity, including a novel lead compound not previously investigated. By focusing screening on the highest probability hits, AI enables rapid lead generation while minimizing wasted experiments.
Once hit compounds are found, they undergo lead optimization to improve potency, selectivity, and drug-like properties. This iterative process traditionally requires synthesizing and testing hundreds of derivatives, taking 1-2 years per lead. AI de novo drug design techniques can automatically generate optimized lead structures.
Atomwise’s AI platform invents virtual derivatives for a lead compound, evaluates their drug-likeness, and outputs design ideas expected to have improved target performance. In a case study, Atomwise proposed over 300 derivatives, from which 5 were synthesized and showed 10-50X greater efficacy than the original lead. By exponentially increasing exploration of chemical space, AI lead optimization can deliver higher quality leads in mere months rather than years.
Preclinical Development
Before a drug can be tested in humans, it must undergo extensive preclinical studies to establish safety and efficacy. Animal testing and cell assays are used to assess toxicity, pharmacokinetics, and activity, costing millions of dollars over 2-3 years per compound. AI simulation models can supplement physical experiments to identify adverse effects earlier.
Insilico Medicine developed an AI model called PandaOmics that predicts the absorption, distribution, metabolism, excretion, and toxicity (ADMET) of small molecule drugs without animal testing. By analyzing drug-like compounds and their ADMET data from public databases, PandaOmics achieved 90% predictive accuracy on key preclinical endpoints. Reducing late-stage animal studies with AI modeling can accelerate preclinical timelines by 1-2 years.
Clinical Trials
Clinical trials account for nearly 60% of total biopharma R&D costs. Enrolling participants with the right inclusion criteria is time-consuming, causing 1/3 of trials to be delayed. AI can mine electronic health records to identify eligible patients 50% faster, reducing enrollment periods from months to weeks.
AI also enables more efficient trial design and management. Insilico Medicine used AI to design a 30-patient Phase 1 trial that reduced the number of arms from 20 to 3, decreasing trial complexity by 85%. Other companies like IQVIA are developing AI systems to forecast patient enrollment rates, optimize site selection, and assign site workload. Applying AI to streamline trials can cut development timelines by 6-12 months.
Manufacturing
Biomanufacturing involves cultivating living cells to produce biologic drugs and is constrained by lengthy production cycles. Cells must grow for 2+ weeks per batch, limiting throughput. AI process modeling can optimize growth conditions and media feeding strategies to increase yields.
Using AI-generated data, Berkeley Lights optimized cell line selection and bioreactor parameters to achieve a 50% boost in antibody titers. Continuous bioprocessing platforms like Univercells use AI to digitally control feeding rates and production variables, reducing manufacturing time by up to 40%. AI-enabled advances in bioprocessing can substantially increase manufacturing speed and capacity.
The Future of AI in Biotech
In the near future, AI will become integral to every step of biopharma R&D, transforming how drugs are discovered and made. According to a McKinsey analysis, integrating AI throughout pharmaceutical value chains could increase R&D productivity by up to 70%. From target identification to clinical trials, AI solutions will continue to overcome bottlenecks and supercharge development timelines.
Within 5 years, AI-designed new drugs could directly enter human trials without preclinical testing, skipping animal studies altogether. Entire discovery programs from start to finish could be completed in just 2-3 years rather than the typical 5-7 years. AI-optimized biomanufacturing will enable 6-12 month production cycles, twice as fast as today. The net result will be radically faster time-to-market for new therapies.
AI will also expand the breadth of druggable targets and treatments. Human intuition and standard techniques struggle to elucidate complex biological mechanisms. AI can unravel new insights from multifaceted omics data, opening up entire target classes previously hidden in the genome. Computational drug design can explore chemical spaces far beyond the reach of manual methods, leading to novel compound architectures. The future of biopharma will involve not just faster development, but more expansive possibilities driven by AI.
Practical Applications
Here are 5 key ways biotech companies can practically apply AI to accelerate workflows:
1. Use AI virtual screening to prioritize compounds for high-throughput target screening. This focuses experiments on the most promising hits.
2. Employ AI de novo drug design to automatically generate and evaluate derivatives of hit and lead compounds. This enhances lead optimization.
3. Leverage AI predictive modeling to supplement physical experiments in preclinical testing. This reduces late-stage animal studies.
4. Apply AI to clinical trial design, patient recruitment, and site selection. This optimizes trial execution and enrollment.
5. Implement AI process modeling and control for biomanufacturing. This increases yields and throughput.
Conclusion
The biotech industry is ripe for an AI revolution. From target discovery through manufacturing, AI is breaking down bottlenecks that have hampered R&D productivity for decades. Integrating AI throughout biopharma promises to massively shorten development timelines, accelerate the delivery of new therapies, and unlock novel innovations. Biotech needs to fully embrace AI’s potential to drive the next wave of transformative change through exponentially greater speed and efficiency. The future of biotechnology will undoubtedly be AI-powered.
Citations:
[1] https://www.sciencedirect.com/science/article/pii/S1871678423000031
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577280/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505413/
[4] https://www.mckinsey.com/industries/life-sciences/our-insights/ai-in-biopharma-research-a-time-to-focus-and-scale
[5] https://youtube.com/watch?v=gLny1q5WTos
[6] https://www.dni.gov/files/images/globalTrends/GT2040/NIC-2021-02494--Future-of-Biotech--Unsourced--14May21.pdf
Comments